Business Context and Reporting Period
Company: Inspire Medical Systems, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 5, 2026 (Earliest event reported)
Reporting Period: The filing references financial results for the quarter and full year ended December 31, 2025, announced via press release on February 11, 2026.
Key Financial Metrics
This Form 8-K serves as a notification of a press release and does not contain specific financial data tables. The filing states that the full text of the press release containing revenue, profit, cash flow, margins, debt, and liquidity metrics is furnished as Exhibit 99.1. Consequently, this filing text does not provide clear values for these specific financial metrics.
Material Changes and Corporate Governance
- Board Structure Proposal: The Company intends to propose an amendment to its Seventh Amended and Restated Certificate of Incorporation at the 2026 Annual Meeting to declassify the Board of Directors and provide for the annual election of directors following a phase-in period.
- Bylaw Amendments: On February 5, 2026, the Board approved Amended and Restated Bylaws (effective upon stockholder approval of the charter amendment). These amendments remove the provision that directors may be removed only for cause, aligning removal procedures with applicable Delaware General Corporation Law.
Guidance, Outlook, and Risks
- Investor Communications: The Company plans to participate in meetings with investors and analysts in February and March 2026. Presentation materials for these meetings are included as Exhibit 99.2.
- Forward-Looking Statements: The filing explicitly states that the information in Item 2.02 (financial results) and Item 7.01 (presentation materials) is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Important Facts for Investor Verification
- Review Exhibit 99.1 (Press Release dated February 11, 2026) for actual financial performance data for Q4 and Full Year 2025.
- Verify the status of the proposed Charter Amendment and Bylaw changes at the upcoming 2026 Annual Meeting of Stockholders.
- Examine Exhibit 99.2 for management's presentation materials and any updated guidance provided during February/March 2026 investor meetings.